In recent years, the "soul bargaining" of the adjustment of the national medical insurance drug catalog has been the focus of the year-end hot search list. After multiple rounds of negotiations, many new and good drugs with high clinical value, urgent needs of patients, and low substitutability have been cut from "sky high" prices to "cabbage prices" and entered the catalog, greatly improving the level of medication security for major diseases and special populations. It is inevitable that medical institutions will be overshadowed by the annual updates. How to bridge the "last mile" of admission and enable clinical patients to use "Guotan Medicine" as soon as possible? On January 31st, the Guangzhou Medical Insurance Bureau held a "Medical Insurance Hospital Enterprise" exchange meeting on the implementation and use of drugs in the 2024 National Medical Insurance Negotiation on Biological Island. This is the first time that Guangzhou Medical Insurance has convened a tripartite collaboration to solve the issue of the implementation of "National Medical Insurance Negotiations". At the meeting, functional departments such as the Provincial Medical Insurance Bureau, Guangzhou Municipal Health Commission, Guangzhou Municipal Bureau of Industry and Information Technology, as well as personnel from 40 public designated medical institutions, 14 local negotiation drug companies, and 4 negotiation drug distribution companies had a collision of views. Clinical frontline: The 780000 yuan "sky high price drug" selected for negotiation has a significant "burden reducing" effect on patients, and medical personnel have a deep feeling. Promoting the implementation of negotiation drugs is also seen as an "obligation" by many hospital managers. Gao Kai, vice president of the the Pearl River Hospital of Southern Medical University, gave an example to share at the exchange meeting: Xiao Liu, an 8-year-old child with spinal muscular atrophy (SMA), a rare disease, needs to use the specific drug Nocin Sodium Injection. When it was first launched in China, the exorbitant price of 780000 yuan for this drug left many patients feeling pain beyond reach. After being included in the "soul bargaining" of "not giving up on every small group", the price of Noxinasone sodium was reduced to 33000 yuan, a decrease of over 95%. After being reimbursed by medical insurance and medical assistance, the individual self paid expenses of this patient were only 807 yuan. Gao Kai introduced that in order to promote the implementation of national negotiated drugs in clinical practice, the hospital pays close attention to the adjustment of the catalog, timely holds pharmaceutical meetings, and links the drug allocation with the adjustment of the medical insurance drug catalog. If it is temporarily unable to be included in the hospital's supply catalog and there is indeed a clinical demand, a temporary procurement green channel will be opened; The medication for rare diseases is purchased by a dedicated person. It is reported that the annual dynamic adjustment of the National Medical Insurance Drug Catalogue has been implemented since 2019, which has initiated the acceleration of new and good drugs entering medical insurance. In the latest version of the list of medical insurance drugs implemented on the 1st of this month, 121 drugs were successfully selected through a new round of negotiations or bidding, covering drugs for anti-tumor, antiviral, rare diseases, chronic diseases, etc., with an average price reduction of 61.7%. At present, there are over 630 designated hospitals in Guangzhou equipped with negotiation drugs. In 2023, a total of 5.059 million insured persons in Guangzhou used negotiation drugs, involving drug costs of 2.8 billion yuan and medical insurance accounting of 1.79 billion yuan. The number of insured persons, drug costs, and accounting costs all increased by more than 30% year-on-year, better ensuring the medication needs of insured patients. The variety of negotiation drugs used in some large tertiary hospitals accounted for more than 50%. Supporting innovation: Promoting the development of local pharmaceutical industry requires time for hospitals and clinical experts to accept new drugs, change medication habits, and gradually adjust diagnosis and treatment plans in clinical practice